Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Therapeutic applications of PARP inhibitors in ovarian cancer

15 May 2020

Abstract excerpt

Ovarian cancer is the most lethal gynecologic malignancy with a high recurrence rate. Poly(ADP-ribose) polymerase inhibitors (PARPi) are one of the most active new therapies for treatment of ovarian cancer. These treatment modalities are based on the mechanisms of "synthetic lethal" and "PARP trapping", especially for patients with homologous recombination deficiencies, and they demonstrate a high survival...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to DNA Repair Mechanisms
Share to Integrated Circuits and Semiconductor Failure Analysis
Share to PARP inhibition in cancer therapy

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 32422564
DOI: 10.1016/j.biopha.2020.110204

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Therapeutic applications of PARP inhibitors in ovarian cancerPMID 32422564Read ↗

Clinical application of PARP inhibitors in ovarian cancer: from molecular mechanisms to the current statusSemantic proximity Read ↗

Mechanism and current progress of Poly ADP-ribose polymerase (PARP) inhibitors in the treatment of ovarian cancerSemantic proximity Read ↗

Update on poly(ADP-ribose) polymerase inhibitors resistance in ovarian cancerSemantic proximity Read ↗

Advances and perspectives of PARP inhibitorsSemantic proximity Read ↗

Clinical Landscape of PARP Inhibitors in Ovarian Cancer: Molecular Mechanisms and Clues to Overcome ResistanceSemantic proximity Read ↗

Emerging strategies to overcome PARP inhibitors' resistance in ovarian cancerSemantic proximity Read ↗

PARP Inhibitors for Ovarian Cancer: Current Indications, Future Combinations, and Novel Assets in Development to Target DNA Damage RepairSemantic proximity Read ↗

Targeting Homologous Recombination Deficiency in Ovarian Cancer with PARP Inhibitors: Synthetic Lethal Strategies That Impact Overall SurvivalSemantic proximity Read ↗

Fighting resistance: post-PARP inhibitor treatment strategies in ovarian cancerSemantic proximity Read ↗

Treatment of Ovarian Cancer Beyond PARP Inhibition: Current and Future OptionsSemantic proximity Read ↗

Poly (ADP-ribose) polymerase (PARP) as target for the treatment of epithelial ovarian cancer: what to know.Semantic proximity Read ↗

An Update on Poly(ADP-ribose)polymerase-1 (PARP-1) Inhibitors: Opportunities and Challenges in Cancer TherapySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.